VeGen Labs Secures Funding for Lung Cancer Treatment
VeGen Labs, a biotechnology startup incubated at ASPIRE-TBI and ASPIRE-BioNEST within the University of Hyderabad, has been awarded Rs 3.765 crores in funding from the Biotechnology Industry Research Assistance Council (BIRAC). This funding will support the company’s research and development of a KRAS inhibitor, a targeted therapy aimed at treating non-small cell lung cancer (NSCLC).
KRAS mutations are frequently observed in NSCLC, and these mutations often lead to aggressive tumor growth and resistance to existing therapies. The development of effective KRAS inhibitors represents a significant step forward in cancer treatment. VeGen Labs’ project aims to develop a novel therapeutic approach to tackle this challenging form of lung cancer.
“We are honored to receive this grant from BIRAC,” said a spokesperson for VeGen Labs. “This funding will enable us to accelerate our research efforts and bring a potentially life-saving treatment to patients suffering from non-small cell lung cancer,” they added. The company plans to use the funds to advance pre-clinical studies and move towards clinical trials.
This significant funding boost highlights the growing importance of Indian biotechnology companies in developing innovative healthcare solutions. VeGen Labs’ focus on a KRAS inhibitor exemplifies the targeted approach to cancer treatment, which offers the potential for improved outcomes and reduced side effects compared to traditional chemotherapy methods.
The BIRAC funding will assist VeGen Labs with critical resources for conducting research and development activities necessary to move its KRAS inhibitor through the various stages of drug discovery. The company is dedicated to addressing unmet medical needs in oncology and is excited about the potential of its research to make a meaningful difference in the lives of those affected by lung cancer.
